Business Wire

VA-THREATCONNECT

Share
ThreatConnect Upgrades the Most Advanced Threat Intelligence Platform with Release of ThreatConnect 4.0

ThreatConnect® , Inc., today announced ThreatConnect 4.0 , the latest version of the industry’s only true threat intelligence platform (TIP). Immediately available for all customers, ThreatConnect 4.0 offers customized reporting catering to Directors and the C-suite, making it easy for these stakeholders to evaluate threat intelligence. Security Directors can easily see the impact threat intelligence is having across their organization and make real-time playbook and workflow decisions to maximize efforts. Plus, chief information security officers (CISO) gain a much-demanded ability to measure the return on investment (ROI) of Threat Intelligence.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160126005446/en/

"Cyber threats are no longer solely a problem for security teams and analysts, the stakes and prevalence of data breaches affect more organizations’ missions and bottom line, making this a greater area of C-Suite and board-level involvement,” said ThreatConnect CEO Adam Vincent. “While we often refer to our platform as ‘made for analysts, by analysts’, we recognize the need to deliver insights that are easily digestible from the security analyst all the way to the CISO, in one platform, and that’s exactly what we’ve done with ThreatConnect 4.0.”

There are several additional differentiators within ThreatConnect 4.0 including the ability to distinguish the quality, relevance and accuracy (false positives) of intelligence sources being evaluated. In an easily understood visual, ThreatConnect 4.0 is grouped in four sections: sources, indicators, intelligence, and activities. An overview of all assessed data from within the organization, specified communities and threat feeds is provided all on one screen. All sources of indicators are then plotted on a ‘threat rating versus confidence’ quadrant, making it effortless to compare and contrast the greatest areas of concern. These new features enable executives, security teams and analysts to collaborate and make faster, informed decisions on how to invest time and resources, dramatically improving security ROI.

ThreatConnect 4.0 also boasts a new user interface, with an improved, easy to navigate dashboard and intuitive views of team workflows and collaboration to enhance helping security staffs and managers readily understanding of what is happening and what is important with a simple glance.

ThreatConnect 4.0 includes previous aspects as well, most notably its ability to be both on-premises and in cloud – the only TIP in the market with this capability – to flexibly suit different organizations’ requirements. In addition, ThreatConnect 4.0 continues to offer access to the highly valuable TC Exchange, which allows users to join or create their own communities - accessing open source and premium feeds to enhance intelligence gathering. Also within TC Exchange, users can build, host and share secure, customized applications that enable better contextual intelligence gathering, analysis and sharing.

Read more about ThreatConnect 4.0 at “What’s New in ThreatConnect 4.0 .”

About ThreatConnect

ThreatConnect, Inc. is the leading provider of threat intelligence products and services including ThreatConnect®, the most widely adopted Threat Intelligence Platform (TIP) on the market. ThreatConnect delivers a single platform in the cloud and on-premises to effectively aggregate, analyze, and act to counter sophisticated cyber-attacks. Designed to engage security teams at all levels of maturity, ThreatConnect is used globally by organizations just getting their threat intelligence programs started as well as more than 40% of the Fortune 100. Leveraging advanced analytics capabilities ThreatConnect offers a superior understanding of relevant cyber threats to business operations. Learn more about our products and services, visit: www.threatconnect.com .

Contact:

PR Contact
W2 Communications
Nicole Nolte, 703-877-8111
Nicole.Nolte@w2comm.com

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Daiichi Sankyo Announces the Initiation of the Development of Oral Triple Combination Lipid-Lowering Tablets to Support the Management of LDL-C30.8.2025 18:00:00 CEST | Press release

Initiation of the development of new oral triple combination tablets, aimed at improving adherence and outcomes in low-density lipoprotein cholesterol (LDL-C) management. Recent findings from MILOS and SANTORINI registries presented at ESC Congress 2025, highlight ongoing challenges in accurately assessing cardiovascular (CV) risk and helping patients reach LDL-C targets.1-5 Furthermore, data from a four-country cohort of the MILOS study support the real-world effectiveness and safety of bempedoic acid in both sexes.6 Simulation using SANTORINI data reveals the potential of improved LDL-C goal attainment with tailored oral combination therapy of statins, ezetimibe and bempedoic acid, in line with the latest 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias.7,8 Daiichi Sankyo has a long-standing commitment to easing treatment of cardiovascular disease (CVD) and exploring new treatment options that improve CVD outcomes and treatment adherence. Daiich

Alnylam to Advance Zilebesiran into Global Phase 3 Cardiovascular Outcomes Trial30.8.2025 16:30:00 CEST | Press release

- Phase 3 Trial Informed by KARDIA-3 Phase 2 Study Results Presented as a Late-Breaking Abstract at the European Society of Cardiology Congress 2025 -- Zilebesiran Demonstrated Clinically Meaningful Reductions in Office Systolic Blood Pressure in Patients with Uncontrolled Hypertension and High Cardiovascular Risk at Month 3 Primary Endpoint, with Continuous Control Through Month 6 -- Zilebesiran Displayed Encouraging Safety When Combined with Two or More Antihypertensives -- Results Support Biannual Dosing Regimen and Inform Phase 3 Trial Design: Trial Expected to Initiate by Year-End 2025 -- Alnylam to Host Webcast Investor Event on August 30, 2025, at 1:00 pm ET (7:00 pm CEST) - Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced plans to initiate a Phase 3 cardiovascular outcomes trial (CVOT) to evaluate the potential of zilebesiran to reduce the risk of major adverse cardiovascular events. This decision is informed by results from t

Andersen Consulting styrker sine kompetencer inden for virksomhedstransformation med Fabric29.8.2025 17:01:00 CEST | Pressemeddelelse

Andersen Consulting udvider sin platform gennem en samarbejdsaftale med Fabric, der er et strategisk designfirma, der arbejder med organisationer for at integrere bæredygtighed, forsyningskæder og menneske-centreret innovation på tværs af kultur og drift. Fabric blev grundlagt i Japan i 2021 og arbejder sammen med virksomheder og globale brands om at skabe regenerative forretningsmodeller sammen samt bæredygtige brandstrategier og fremtidssikrede produkter. Ved hjælp af strategiske designmetoder og designfilosofi skaber virksomheden indsigtsbaseret transformation på tværs af forsyningskæder, brand og HR. Fabric er kendt for sin systemtænkning og sit engagement i social og miljømæssig bæredygtighed og fremmer desuden digitale transformationsinitiativer, der integrerer bæredygtighed, humankapital og AI. "Fabric er skabt for at hjælpe virksomheder med at blomstre gennem regenerative relationer til mennesker, samfund og forbundne, levende systemer," sagde James Hollow, der er grundlægger a

Andersen Consulting tilføjer samarbejdsfirmaet Skribble29.8.2025 16:28:00 CEST | Pressemeddelelse

Andersen Consulting udvider sine kompetencer inden for strategi og virksomhedstransformation gennem en samarbejdsaftale med Skribble, der er et rådgivningsfirma inden for digital teknologi og branding, der hjælper virksomheder i Sydøstasien med innovation og driftsmæssig transformation. Skribble, der blev etableret i 2020, tilbyder en bred vifte af services, herunder brand- og kommunikationsstrategi, digital markedsføring, specialudvikling af teknologi, forandringsledelse og platformsløsninger. Virksomheden hjælper organisationer inden for ejendomme, forbrugsvarer, bankverdenen og den offentlige sektor ved at sikre, at strategi og eksekvering er tæt forbundet – med henblik på at levere integrerede løsninger inden for brand, performance og teknologi. Skribbe fokuserer på procesoptimering har kreative og tekniske kompetencer, der hjælper kunderne med at skabe forandringer og vækst. "Hos Skribble arbejder vi på at omsætte kreativ energi til strategiske resultater," sagde Chan Leong, CEO f

BeOne Medicines Announces Positive Topline Results for Sonrotoclax in Relapsed or Refractory Mantle Cell Lymphoma (MCL)29.8.2025 12:00:00 CEST | Press release

Study met its primary endpoint of overall response rate (ORR), demonstrating clinically meaningful responses in rare B-cell lymphoma with high unmet needBeOne to submit data to global regulatory authorities for their review and potential approval BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from a Phase 1/2 study (BGB-11417-201) of sonrotoclax, a next-generation and potentially best-in-class investigational BCL2 inhibitor, in adult patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL), following treatment with a Bruton’s tyrosine kinase inhibitor (BTKi) and anti-CD20 therapy. BeOne plans to present the full data at an upcoming medical meeting. “For people with relapsed or refractory mantle cell lymphoma, the disease is aggressive, the treatment landscape fragmented, and the outcomes unacceptably poor. These topline results for sonrotoclax underscore its potential to deliver meaningful and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye